Introducing EPKINLY1

A novel T-cell engaging bispecific antibody that binds CD3/CD20

Select to learn about specific MOA functions

EPKINLY™ targets CD3/CD20.
T-cell activation

In vitro, EPKINLY activated T cells, caused the release of proinflammatory cytokines, and induced lysis of B cells.

Humanized bispecific IgG1 antibody

EPKINLY is a humanized bispecific IgG1 antibody, T-cell engaging bispecific antibody that binds to CD20 on B cells and to CD3 on T cells.

CD20-expressing B cell

CD20 is expressed on the surface of lymphoma cells and healthy B-lineage cells.

CD3=cluster of differentiate 3; CD20=cluster of differentiate 20; IgG1=immunoglobulin G subclass 1; MOA=mechanism of action.

" "

Learn about the EPCORETM NHL-1 trial